Bigfoot Biomedical is a highly competitive player in medtech’s race to develop an artificial pancreas. The 50-person company has made rapid progress towards developing a smart, automated insulin delivery system since its beginnings in 2014. Just yesterday Bigfoot announced that it is partnering with Abbott, bringing together Abbott’s FreeStyle Libre glucose monitoring tech and Bigfoot’s insulin delivery platform. Medical Design & Outsourcing managing editor, Chris Newmarker, spoke with the company’s co-founder & CEO, Jeffrey Brewer, about its efforts to bring a secure, connected device to market.
Newmarker: Where are things right now with Bigfoot’s smart loop system?
Brewer: We are about three years into the journey with Bigfoot Biomedical. We have developed an automated insulin delivery system that we believe is the first class three medical device drug delivery system [for insulin]. It is a true internet-of-things secure device that uses a smartphone as an interface to the system, where you can announce a delivery of insulin from the phone and that phone is connected to the cloud. We created an entire system to simplify insulin administration, to make it as safe and as supported by data science as possible. And to make life easier, for people with Type I diabetes.